1. Home
  2. CIGL vs ICCC Comparison

CIGL vs ICCC Comparison

Compare CIGL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CIGL

Concorde International Group Ltd Class A Ordinary Shares

N/A

Current Price

$2.04

Market Cap

59.4M

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$6.03

Market Cap

55.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIGL
ICCC
Founded
1997
1982
Country
Singapore
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.4M
55.5M
IPO Year
2025
1987

Fundamental Metrics

Financial Performance
Metric
CIGL
ICCC
Price
$2.04
$6.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.0K
22.4K
Earning Date
09-29-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$11,072,733.00
$27,769,304.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$24.05
Revenue Growth
6.32
16.49
52 Week Low
$1.40
$4.28
52 Week High
$31.06
$7.60

Technical Indicators

Market Signals
Indicator
CIGL
ICCC
Relative Strength Index (RSI) N/A 63.79
Support Level N/A $4.72
Resistance Level N/A $5.36
Average True Range (ATR) 0.00 0.34
MACD 0.00 0.18
Stochastic Oscillator 0.00 98.09

Price Performance

Historical Comparison
CIGL
ICCC

About CIGL Concorde International Group Ltd Class A Ordinary Shares

Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: